U.S. Ranbaxy Court Action Stirs Concern In Indian Drug Industry
This article was originally published in PharmAsia News
India's generic drug industry is concerned U.S. government accusations of adulterated drugs marketed by Ranbaxy Laboratories could have a widespread effect. Some industry representatives expect anti-generics lobbyists to take advantage of the lawsuit. The industry experts also believe the entire Indian drug-making industry, which has enjoyed a good safety record, could become viewed with caution. There also is the possibility of medical professionals around the world becoming suspicious of Indian products. (Click here for more
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.